Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis...

UCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a successful appeal against a rejection with help fro

Vitamin K Market will reach over $1,000 million by 2025

Vitamin K Market will achieve over 8% CAGR up to 2025

Lilly faces biosimilar rivals to osteoporosis drug Forsteo i...

CHMP says no to Amgen’s osteoporosis drug Evenity

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.

FDA advisers back Amgen/UCB's osteoporosis drug Evenity

Amgen’s bone-building drug Evenity looks on course for US approval in certain women with osteoporosis after a panel of advisers strongly backed it, but cardiac safety worries mean that it w